全文获取类型
收费全文 | 125179篇 |
免费 | 10379篇 |
国内免费 | 3269篇 |
专业分类
耳鼻咽喉 | 1266篇 |
儿科学 | 7182篇 |
妇产科学 | 3836篇 |
基础医学 | 13607篇 |
口腔科学 | 1787篇 |
临床医学 | 13331篇 |
内科学 | 21018篇 |
皮肤病学 | 2465篇 |
神经病学 | 10769篇 |
特种医学 | 2898篇 |
外国民族医学 | 4篇 |
外科学 | 11319篇 |
综合类 | 18514篇 |
现状与发展 | 16篇 |
一般理论 | 1篇 |
预防医学 | 7132篇 |
眼科学 | 2264篇 |
药学 | 6903篇 |
54篇 | |
中国医学 | 12347篇 |
肿瘤学 | 2114篇 |
出版年
2024年 | 123篇 |
2023年 | 2142篇 |
2022年 | 3321篇 |
2021年 | 5804篇 |
2020年 | 5609篇 |
2019年 | 4420篇 |
2018年 | 4486篇 |
2017年 | 4615篇 |
2016年 | 4755篇 |
2015年 | 4533篇 |
2014年 | 8849篇 |
2013年 | 9203篇 |
2012年 | 7218篇 |
2011年 | 8418篇 |
2010年 | 6515篇 |
2009年 | 6293篇 |
2008年 | 6096篇 |
2007年 | 6242篇 |
2006年 | 5629篇 |
2005年 | 4683篇 |
2004年 | 3988篇 |
2003年 | 3581篇 |
2002年 | 2504篇 |
2001年 | 2224篇 |
2000年 | 1862篇 |
1999年 | 1677篇 |
1998年 | 1242篇 |
1997年 | 1114篇 |
1996年 | 1096篇 |
1995年 | 1285篇 |
1994年 | 1090篇 |
1993年 | 986篇 |
1992年 | 881篇 |
1991年 | 703篇 |
1990年 | 646篇 |
1989年 | 536篇 |
1988年 | 531篇 |
1987年 | 485篇 |
1986年 | 421篇 |
1985年 | 540篇 |
1984年 | 453篇 |
1983年 | 288篇 |
1982年 | 374篇 |
1981年 | 325篇 |
1980年 | 269篇 |
1979年 | 230篇 |
1978年 | 144篇 |
1977年 | 110篇 |
1976年 | 96篇 |
1975年 | 40篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
61.
62.
63.
《Vaccine》2022,40(16):2370-2378
Porcine reproductive and respiratory syndrome virus (PRRSV) and Mycoplasma hyopneumoniae (M. hyopneumoniae, Mhp) are two of the most common pathogens involved in the porcine respiratory disease complex (PRDC) resulting in significant economic losses worldwide. Vaccination is the most effective approach to disease prevention. Since PRRSV and Mhp co-infections are very common, an efficient dual vaccine against these pathogens is required for the global swine industry. Compared with traditional vaccines, multi-epitope vaccines have several advantages, they are comparatively easy to produce and construct, are chemically stable, and do not have an infectious potential. In this study, to develop a safe and effective vaccine, B cell and T cell epitopes of PRRSV-GP5, PRRSV-M, Mhp-P46, and Mhp-P65 protein had been screened to construct a recombinant epitope protein rEP-PM that has good hydrophilicity, strong antigenicity, and high surface accessibility, and each epitope is independent and complete. After immunization in mice, rEP-PM could induce the production of high levels of antibodies, and it had good immunoreactivity with anti-rEP-PM, anti-PRRSV, and anti-Mhp antibodies. The anti-rEP-PM antibody specifically recognizes proteins from PRRSV and Mhp. Moreover, rEP-PM induced a Th1-dominant cellular immune response in mice. Our results showed that the rEP-PM protein could be a potential candidate for the development of a safe and effective multi-epitope peptide combined vaccine to control PRRSV and Mhp infections. 相似文献
64.
Wattana Leowattana Tawithep Leowattana Pathomthep Leowattana 《World Journal of Clinical Cases》2022,10(34):12470-12483
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has triggered a widespread outbreak since December 2019. The SARS-CoV-2 infection-related illness has been dubbed the coronavirus disease 2019 (COVID-19) by the World Health Organization. Asymptomatic and subclinical infections, a severe hyper-inflammatory state, and mortality are all examples of clinical signs. After attaching to the angiotensin converting enzyme 2 (ACE2) receptor, the SARS-CoV-2 virus can enter cells through membrane fusion and endocytosis. In addition to enabling viruses to cling to target cells, the connection between the spike protein (S-protein) of SARS-CoV-2 and ACE2 may potentially impair the functionality of ACE2. Blood pressure is controlled by ACE2, which catalyzes the hydrolysis of the active vasoconstrictor octapeptide angiotensin (Ang) II to the heptapeptide Ang-(1-7) and free L-Phe. Additionally, Ang I can be broken down by ACE2 into Ang-(1-9) and metabolized into Ang-(1-7). Numerous studies have demonstrated that circulating ACE2 (cACE2) and Ang-(1-7) have the ability to restore myocardial damage in a variety of cardiovascular diseases and have anti-inflammatory, antioxidant, anti-apoptotic, and anti-cardiomyocyte fibrosis actions. There have been some suggestions for raising ACE2 expression in COVID-19 patients, which might be used as a target for the creation of novel treatment therapies. With regard to this, SARS-CoV-2 is neutralized by soluble recombinant human ACE2 (hrsACE2), which binds the viral S-protein and reduces damage to a variety of organs, including the heart, kidneys, and lungs, by lowering Ang II concentrations and enhancing conversion to Ang-(1-7). This review aims to investigate how the presence of SARS-CoV-2 and cACE2 are related. Additionally, there will be discussion of a number of potential therapeutic approaches to tip the ACE/ACE-2 balance in favor of the ACE-2/Ang-(1-7) axis. 相似文献
65.
66.
《Human immunology》2022,83(12):803-807
We examined the correlation between class I HLA evolutionary divergence (HED), a surrogate for the capacity to present different peptides, and the outcomes of 234 adult inpatients with confirmed SARS-CoV-2 infection. Genomic DNA was extracted from peripheral blood and genotyped by next-generation sequencing (NGS). HED scores for HLA class I (HLA-A, -B, and -C) genotypes were calculated using Grantham’s distance. Higher HED scores for HLA-B, but not HLA-A or -C, are significantly associated with a decreased probability of poor outcomes including ICU admission, mechanical ventilation, and death (OR = 0.93; P = 0.04) in the univariate analysis. In the multivariate analysis, increased HLA-B HED score, younger age, and no comorbidity were independently associated with favorable outcomes (P = 0.02, P = 0.01, and P = 0.05, respectively). This finding is consistent with the notion that broader peptide repertoires presented by class I HLA may be beneficial in infection control. 相似文献
67.
《European journal of medical genetics》2022,65(6):104496
Pathogenic variants in the OFD1 gene have been classically associated with the Orofaciodigital syndrome type 1 in females, a condition previously considered to be X-linked dominant with male embryonic lethality. However, an increasing number of males with pathogenic OFD1 variants who survived beyond the neonatal period have now been reported in the literature. Although each new report has added to the ever-broadening spectrum of clinical findings seen in males, many questions about genotype-phenotype correlations and disease mechanism remain. Herein, we describe a 9-year-old male child with a novel hemizygous pathogenic OFD1 variant identified by exome sequencing and a unique combination of findings, not previously reported, including presence of both a hypothalamic hamartoma and the molar tooth sign. His clinical features overlap multiple ciliopathy phenotypes, blurring the boundaries of distinct ciliopathy gene-disease relationships. This case provides further evidence for the consideration of a broad OFD1-relateddisorder spectrum in affected males rather than multiple distinct phenotypes. Additionally, a review of previously published cases of the disorder in males support the inclusion of the OFD1 gene in the differential diagnosis and work up for all individuals who present with primary ciliopathy-type features, regardless of their gender. We also highlight current information about OFD1 variant types and pathogenesis and explore how these could mechanistically drive some of the observed phenotypic differences. 相似文献
68.
Sine Wichmann Martin Schønemann-Lund Anders Perner Theis S. Itenov Theis Lange Christian Gluud Rasmus E. Berthelsen Anne C. Brøchner Jørgen Wiis Morten H. Bestle 《Acta anaesthesiologica Scandinavica》2023,67(4):470-478
Background
Salt and water accumulation leading to fluid overload is associated with increased mortality in intensive care unit (ICU) patients, but diuretics' effects on patient outcomes are uncertain. In this first version of the GODIF trial, we aimed to assess the effects of goal-directed fluid removal with furosemide versus placebo in adult ICU patients with fluid overload.Methods
We conducted a multicentre, randomised, stratified, parallel-group, blinded, placebo-controlled trial in clinically stable, adult ICU patients with at least 5% fluid overload. Participants were randomised to furosemide versus placebo infusion aiming at achieving neutral cumulative fluid balance as soon as possible. The primary outcome was the number of days alive and out of the hospital at 90 days.Results
The trial was terminated after the enrolment of 41 of 1000 participants because clinicians had difficulties using cumulative fluid balance as the only estimate of fluid status (32% of participants had their initially registered cumulative fluid balance adjusted and 29% experienced one or more protocol violations). The baseline cumulative fluid balance was 6956 ml in the furosemide group and 6036 ml in the placebo group; on day three, the cumulative fluid balances were 1927 ml and 5139 ml. The median number of days alive and out of hospital at day 90 was 50 days in the furosemide group versus 45 days in the placebo group (mean difference 1 day, 95% CI -19 to 21, p-value .94).Conclusions
The use of cumulative fluid balance as the only estimate of fluid status appeared too difficult to use in clinical practice. We were unable to provide precise estimates for any outcomes as only 4.1% of the planned sample size was randomised. 相似文献69.
70.
目的 探讨儿童腹型过敏性紫癜(AHSP)不同中医证候的临床及尿液蛋白特征。方法 按照诊断及纳入、排除标准,收集AHSP不同中医证候患儿的临床信息及尿样进行分析,并通过尿液蛋白质组质谱分析,筛选及比较AHSP不同证候的尿液差异蛋白。结果 AHSP不同证候临床特征显示,皮肤紫癜首发者风热伤络证最多,湿毒内蕴证次之;皮肤紫癜伴腹痛症状首发者仅在脾虚不摄证中出现。不同证候间实验室指标未出现统计学差异。通过DDA及DIA定量方法,在不同证候间筛选出21个证候差异蛋白,其中风热伤络、湿毒内蕴证间2个,风热伤络、脾虚不摄证间3个,湿毒内蕴、脾虚不摄证间16个;经OPLS-DA分析筛选出10个差异蛋白,包括ALDOB、Glyc、GSTA2、GPDA、GAPDH、CRYL1、AK1A1、VMO1、Cat S、DHPR。结论 AHSP不同证候间临床及尿液蛋白存在差异,这些差异可为腹型过敏性紫癜的证候诊断提供一定的帮助。 相似文献